drugset / Trial / NCT00616694

Impact of Vertebral Fracture Knowledge on Persistence in Subjects Taking Glucocorticoid Therapy

NCT00616694

Phase 4 Completed 248 enrolled Sanofi
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the effect of subject knowledge of their disease status on persistence in subjects receiving Actonel 5 mg daily over a 12-month period for the prevention and treatment of GIO.

Timeline

Start
2002-07
Primary completion
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Risedronate Small molecule 5 mg Oral
Background Calcium carbonate Other / unclassified 500 mg
Background Vitamin D Other / unclassified 200 iu

Indications